Corcept Therapeutics is a pioneering biotechnology company dedicated to unlocking the potential of cortisol modulation. With over 25 years of expertise, they have developed more than 1,000 selective cortisol modulators and secured FDA approval for the first treatment for hypercortisolism (Cushing’s syndrome). The company continues to drive innovation across endocrinology, oncology, metabolism, and neurology through ongoing research and development.
Corcept is a research and development company focused on novel cortisol modulators. They have secured FDA approval for Korlym®, the first approved treatment for Cushing's syndrome, and are continually advancing their research to improve disease treatment. This Associate Director role leads Corcept's Document Control Program, ensuring compliance with Good Manufacturing Practices (GMP) and maintaining a quality assurance program.
Corcept Therapeutics is a pioneering biotechnology company dedicated to unlocking the potential of cortisol modulation. With over 25 years of expertise, they have developed more than 1,000 selective cortisol modulators and secured FDA approval for the first treatment for hypercortisolism (Cushing’s syndrome). The company continues to drive innovation across endocrinology, oncology, metabolism, and neurology through ongoing research and development.
Corcept Therapeutics